Testing peginterferon alfa-2b with HIV treatment for hepatitis B in adults with HIV
Studies peginterferon alfa-2b with HIV medicines in adults who have HIV and hepatitis B.
Plain-language title generated from the registry record
Registry title: Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients
Key facts
- Where
- Guangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05988879, who can take part
Where in China
- Guangzhou Eighth People's Hospital, Guangzhou Medical UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangzhou 8th People's Hospital
- Trial code
- NCT05988879
- Record updated
- 14 August 2023
- Original description
Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patientsRead full original descriptionShow less
A Clinical Research on Functional Cure Strategies for Hepatitis B Among HIV/HBV Co-infected Patients in China
Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients
Inclusion: Age 18-65 years old, gender unrestricted; Meeting the People's Republic of China Health Industry Standard (WS293-2008) - "AIDS and HIV Infection Diagnostic Criteria", confirmed as HIV-1 infected; HBsAg positive for more than 6 months; At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg <1000IU/mL, HBeAg negative, HBV DNA <100IU/ml, CD4+T lymphocyte count >200 cells/μL and HIV-RNA<20 copies/ml.
Exclusion: Excessive alcohol (average daily alcohol intake >40g for men, >20g for women) or drug users; Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy; Co-infected with Hepatitis A, C, D, or E viruses; With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver; With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus; Post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment; With severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes; Participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.